

```
15 16 17 18 19
ring nodes:
    1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds:
    1-15 13-19 15-16 16-17 16-18
ring bonds:
    1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
exact/norm bonds:
    1-15 4-7 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14 13-19 15-16 16-17
16-18
normalized bonds:
    1-2 1-6 2-3 3-4 4-5 5-6
```

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

Connecting via Winsock to STN

NEWS 36 Dec 17

Welcome to STN International! Enter x:x LOGINID:ssspta1611hxl PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS "Ask CAS" for self-help around the clock NEWS 2 Apr 08 BEILSTEIN: Reload and Implementation of a New Subject Area NEWS Apr 09 Apr 09 ZDB will be removed from STN NEWS NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS 6 Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS Apr 22 Federal Research in Progress (FEDRIP) now available NEWS 8 Apr 22 New e-mail delivery for search results now available NEWS 9 Jun 03 Jun 10 MEDLINE Reload NEWS 10 NEWS 11 Jun 10 PCTFULL has been reloaded FOREGE no longer contains STANDARDS file segment NEWS 12 Jul 02 USAN to be reloaded July 28, 2002; NEWS 13 Jul 22 saved answer sets no longer valid NEWS 14 Enhanced polymer searching in REGISTRY Jul 29 NETFIRST to be removed from STN NEWS 15 Jul 30 NEWS 16 Aug 08 CANCERLIT reload NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN NEWS 18 Aug 08 NTIS has been reloaded and enhanced NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN IFIPAT, IFICDB, and IFIUDB have been reloaded NEWS 20 Aug 19 NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced NEWS 23 Sep 03 JAPIO has been reloaded and enhanced NEWS 24 Sep 16 Experimental properties added to the REGISTRY file NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985 NEWS 27 Oct 21 EVENTLINE has been reloaded NEWS 28 Oct 24 BEILSTEIN adds new search fields NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002 NEWS 31 Nov 18 DKILIT has been renamed APOLLIT NEWS 32 Nov 25 More calculated properties added to REGISTRY NEWS 33 Dec 02 TIBKAT will be removed from STN NEWS 34 Dec 04 CSA files on STN NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date

TOXCENTER enhanced with additional content

NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN

NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003 NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003

NEWS 38 Dec 30 ISMEC no longer available

NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS 43 Feb 13 CANCERLIT is no longer being updated

NEWS 44 Feb 24 METADEX enhancements

NEWS 45 Feb 24 PCTGEN now available on STN

NEWS 46 Feb 24 TEMA now available on STN

NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation

NEWS 48 Feb 26 PCTFULL now contains images

NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,

CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:57:27 ON 18 MAR 2003

=> fil req

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:57:42 ON 18 MAR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8 DICTIONARY FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP

03/18/2003 Print selected from Online session

PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>

Uploading 10006215.str


.

1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 13:58:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 306 TO ITERATE

100.0% PROCESSED 306 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5071 TO 7169

PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s 11

SAMPLE SEARCH INITIATED 13:58:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 306 TO ITERATE

100.0% PROCESSED 306 ITERATIONS 10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 5071 TO 7169
PROJECTED ANSWERS: 11 TO 389

L3 10 SEA SSS SAM L1

03/18/2003 Print selected from Online session

=> s l1 ful

FULL SEARCH INITIATED 13:58:22 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 6528 TO ITERATE

100.0% PROCESSED 6528 ITERATIONS 136 ANSWERS

SEARCH TIME: 00.00.01

136 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY

SESSION 148.15 148.36

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 18 MAR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2003 VOL 138 ISS 12 FILE LAST UPDATED: 17 Mar 2003 (20030317/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14

5 L4

=> d abs ibib hitstr 1-YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

ANSWER 1 OF '5 CAPLUS COPYRIGHT 2003 ACS

Title compd. (I) was prepd. via reaction of 4b(S)-Benzyl-7(S)-hydroxy-7-AΒ (3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2carboxylic acid (II) with 3-aminomethyl-2-methylpyridine (III) in the presence of carbonyldiimidazole. Thus, II (prepn. given) and carbonyldiimidazole were refluxed 2 h in THF; III in THF was added followed by stirring for 3 h at room temp. to give 69% I.

ACCESSION NUMBER:

2002:330265 CAPLUS

DOCUMENT NUMBER:

136:340594

TITLE:

Preparation of 4b(S)-benzyl-7(S)-hydroxy-7-(3,3,3-

trifluoropropyl) -4b, 5, 6, 7, 8, 8a (R), 9, 10octahydrophenanthrene-2-carboxylic acid

(2-methylpyridin-3-ylmethyl)amide via an amidation

reaction using carbonyldiimidazole.

INVENTOR(S):

Murry, Jerry Anthony; White, Timothy Donald

PATENT ASSIGNEE(S):

Pfizer Products Inc., USA Eur. Pat. Appl., 53 pp.

SOURCE:

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.	KIND DATE	APPLICATION NO. DATE
	EP 1201655	A2 20020502	EP 2001-309057 20011025
	EP 1201655	A3 20020626	5
	R: AT, BE,	CH, DE, DK, ES,	, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
	IE, SI,	LT, LV, FI, RO,	, MK, CY, AL, TR
	US 2002087005	A1 20020704	4 US 2001-8619 20011022
	CN 1356319	A 20020703	3 CN 2001-135596 20011026
	JP 2002193937	A2 20020710	JP 2001-329529 20011026
	BR 2001004836	A 20021015	5 BR 2001-4836 20011029
PRIO	RITY APPLN. INFO	. :	US 2000-243873P P 20001027
OTHER SOURCE(S): CASREACT 136:340594			
IT	418814-84-3P		
	RL: RCT (Reacta	nt); SPN (Synther	etic preparation); PREP (Preparation); RACT
(Reactant or reagent)			
(prepn. of benzylhydroxytrifluoropropyloctahydrophenanthrenecarboxylic			
acid methylpyridinylmethylamide via an amidation reaction)			
RN	418814-84-3 CA		,
CN	Carbamic acid.	[2-(dimethylaming	no)ethyl]methyl-, (4bS,7R,8aR)-
			-hydroxy-4b-(phenylmethyl)-7-
	ED, 3, 0, 1, 0, 0a, 3	, io-occanyaro-/-i	-nydroxy-4b-(phenylmethyl)-/-

(trifluoromethyl) -2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS GI



$$\begin{array}{c} & \text{OH} \\ & \text{R}^2 \\ & \text{N} \end{array}$$

Title compds. [I; R1 = (trifluoromethyl)alkyl, CF3, C.tplbond.CMe, AB C.tplbond.CCl, C.tplbond.CCF3, CH2OA; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H , alkylamino, alkylhet; R3R4N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring contg. 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R7; R7 = (substituted) alkyl; with provisos], were prepd. for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A soln. of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2ethyl-[2R-(2.alpha.,4a.alpha.,10a.beta.)] (prepn. given), COCl2, and Et3N in THF was stirred at room temp. for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS

DOCUMENT NUMBER: 136:340495

TITLE: Preparation of octahydrophenanthrenyl carbamates as

glucocorticoid receptor modulators

INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson,

Ralph Pelton, Jr.

Ι

PATENT ASSIGNEE(S): Pfizer Products Inc., USA SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO.
                                                             DATE
                                            -----
                            _____
                      ----
                            20020502
                                           EP 2001-309064
                                                             20011025
     EP 1201649
                       A1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           JP 2001-328050
                                                             20011025
                            20020710
     JP 2002193911
                       A2
                                           US 2001-6215;
BR 2001-4831
                            20020808
                                                             20011026
     US 2002107235
                       A1
                            20020820
                                                             20011026
     BR 2001004831
                       Α
PRIORITY APPLN. INFO.:
                                        US 2000-243993P P
                                                             20001028
                         MARPAT 136:340495
OTHER SOURCE(S):
     418814-84-3P 419534-40-0P 419534-41-1P
TT
     419534-42-2P 419534-43-3P 419534-44-4P
     419534-45-5P 419534-46-6P 419534-47-7P
     419534-48-8P 419534-49-9P 419534-50-2P
     419534-51-3P 419534-52-4P 419534-53-5P
     419534-54-6P 419534-55-7P 419534-57-9P
     419534-59-1P 419534-60-4P 419534-61-5P
     419534-62-6P 419534-63-7P 419534-64-8P
     419534-65-9P 419534-67-1P 419534-69-3P
     419534-71-7P 419534-73-9P 419534-74-0P
     419534-75-1P 419534-76-2P 419534-79-5P
     419534-80-8P 419534-83-1P 419534-85-3P
     419534-86-4P 419534-87-5P 419534-88-6P
     419534-89-7P 419534-90-0P 419534-91-1P
     419534-92-2P 419534-93-3P 419534-96-6P
     419534-97-7P 419534-98-8P 419535-00-5P
     419535-01-6P 419535-02-7P 419535-03-8P
     419535-04-9P 419535-05-0P 419535-06-1P
     419535-07-2P 419535-08-3P 419535-17-4P
     419535-20-9P 419535-22-1P 419535-24-3P
     419535-26-5P 419535-27-6P 419535-28-7P
     419535-29-8P 419535-31-2P 419535-32-3P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES:
        (prepn. of octahydrophenanthrenyl carbamates as glucocorticoid receptor
        modulators)
     418814-84-3 CAPLUS
RN
CN
     Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-
     4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
     (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)
```

RN 419534-40-0 CAPLUS

Н

F₃C

OH

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN · 419534-41-1 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-42-2 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-43-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-44-4 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-45-5 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-46-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 419534-47-7 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-48-8 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-49-9 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-50-2 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-51-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-52-4 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-53-5 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-54-6 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-55-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-57-9 CAPLUS

CN Carbamic acid, [3-(4-methyl-1-piperazinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ Ph \\ O \\ O \\ \end{array}$$

RN 419534-59-1 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-60-4 CAPLUS

CN Carbamic acid, [3-(hexahydro-1H-azepin-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 419534-61-5 CAPLUS

CN Carbamic acid, methyl(1-methyl-4-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-62-6 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-

octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-63-7 CAPLUS

Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-CN octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN419534-64-8 CAPLUS

Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-CN octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-65-9 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-67-1 CAPLUS

CN Carbamic acid, [2-(1-methyl-2-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-69-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI)

(CA INDEX NAME)

Absolute stereochemistry.

RN 419534-71-7 CAPLUS

CN Carbamic acid, [3-(6-methyl-3,6-diazabicyclo[3.1.1]hept-3-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-73-9 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-74-0 CAPLUS

CN Carbamic acid, methyl(1-methyl-3-pyrrolidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-

(trifluoromethyl) -2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-75-1 CAPLUS

CN Carbamic acid, [(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 OH H

RN 419534-76-2 CAPLUS

CN Carbamic acid, [3-(2-methyl-1-piperidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-79-5 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-

4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-80-8 CAPLUS

CN Carbamic acid, [4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)butyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 419534-83-1 CAPLUS

CN Carbamic acid, (3S)-1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-85-3 CAPLUS

CN Carbamic acid, (3R)-1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-86-4 CAPLUS

CN Carbamic acid, 1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-87-5 CAPLUS

CN Carbamic acid, (2-amino-2-methylpropyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-88-6 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-

4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-89-7 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-90-0 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-91-1 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-203/18/2003

phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

419534-92-2 CAPLUS RN

Carbamic acid, [3-(hexahydro-1H-azepin-1-yl)propyl]-, (4bS,7R,8aR)-CN 4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

419534-93-3 CAPLUS RN

Carbamic acid, [[(2R)-1-ethyl-2-pyrrolidinyl]methyl]-, CN (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl) -2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-96-6 CAPLUS CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ Ph \\ S \\ OH \\ H \end{array}$$

RN 419534-97-7 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} \text{Me} \\ \text{N} \\ \text{CH}_2)_3 \end{array}$$

RN 419534-98-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} \text{Et} \\ \text{N} \\ \text{CH}_2)_{\overline{3}} \\ \text{NMe}_2 \\ \text{OH} \\ \text{H} \end{array}$$

RN 419535-00-5 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-01-6 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-02-7 CAPLUS

CN Carbamic acid, [3-(ethylmethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-03-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-04-9 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & \text{Me} \\ & \\ \text{NEt}_2 \\ \\ \text{F}_3\text{C} & \text{OH} & \text{H} \end{array}$$

RN 419535-05-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-06-1 CAPLUS

CN Carbamic acid, [3-(1-piperidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-07-2 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ R \end{array}$$

RN 419535-08-3 CAPLUS

CN Carbamic acid, (2,2,6,6-tetramethyl-4-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-17-4 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-20-9 CAPLUS

CN Carbamic acid, [[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-22-1 CAPLUS

CN Carbamic acid, [[(2R)-1-ethyl-2-pyrrolidinyl]methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-24-3 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$Me_2N$$
 $(CH_2)_3$
 N
 Me
 Et
 R
 Et
 R

RN 419535-26-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-27-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-28-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-29-8 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-31-2 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-32-3 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$Me-C \equiv C \qquad \qquad 0 \qquad \qquad 0 \qquad \qquad Me$$

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER: 2001:338070 CAPLUS

DOCUMENT NUMBER: 134:336224

TITLE: Use of corticotropin releasing factor (CRF)

antagonists for treating syndrome X

INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): Pfizer Products Inc., USA SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
EP 1097709 A2 20010509 EP 2000-309441 20001026

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

ZA 2000006008 A 20020426 ZA 2000-6008 20001026 PRIORITY APPLN. INFO.: US 1999-162340P P 19991029

OTHER SOURCE(S): MARPAT 134:336224

IT 305822-31-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)

RN 305822-31-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester

03/18/2003

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

$$\begin{array}{c|c} Ph & OH \\ \hline \\ HN & H \end{array}$$

Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2,R3 = null when adjacent dashed line = bond; R4,R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7,R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14,R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepd. as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addn. with Me vinyl ketone in the presence of

ΙI

(S)-(-)-.alpha.-methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone deriv. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, redn. of the enone with lithium and ammonia, addn. of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid deriv. which is coupled with 4-(aminomethyl) pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

2000:790448 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 133:350060

Preparation of nonracemic octahydrophenanthrene and TITLE:

other tricyclic derivs. as selective modulators of

glucocorticoid receptors

Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley INVENTOR(S):

Paul; Swick, Andrew Gordon

Pfizer Products Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 279 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO. DATE
      PATENT NO.
                          KIND DATE
                                 _____
                                                   WO 2000-IB366
      WO 2000066522
                          A1 20001109
                                                                       20000327
          W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
               KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
               DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
               CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                 20020122
                                                 BR 2000-10138
                                                                        20000327
      BR 2000010138
                           Α
      EP 1175383
                           A1
                                 20020130
                                                   EP 2000-911172
                                                                        20000327
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO
                                                                        20000327
                           T2
                                 20021217
                                                   JP 2000-615356
      JP 2002543169
                                 20020430
                                                   US 2000-559384
                                                                        20000427
      US 6380223
                           B1
      NO 2001005272
                           Α
                                 20011228
                                                   NO 2001-5272
                                                                        20011029
                                                   US 2002-80174
                                                                        20020219
      US 2002147336
                           A1
                                 20021010
                                               US 1999-132130P P
                                                                       19990430
PRIORITY APPLN. INFO.:
                                                                    W 20000327
                                                WO 2000-IB366
                                                                    A3 20000427
                                                US 2000-559384
OTHER SOURCE(S):
                             MARPAT 133:350060
      305822-26-8P 305822-28-0P 305822-29-1P
      305822-30-4P 305822-31-5P 305822-32-6P
      305822-33-7P 305822-34-8P 305822-35-9P
      305822-36-0P 305822-37-1P 305822-38-2P
      305822-39-3P 305825-20-1P 305825-21-2P
      305825-22-3P 305825-44-9P 305825-45-0P
      305825-46-1P 305825-48-3P 305826-86-2P
      305826-91-9P 305826-93-1P 305826-98-6P
      305827-03-6P 305827-05-8P 305827-06-9P
      305827-08-1P 305827-11-6P 305827-14-9P
```

305827-29-6P 305827-30-9P 305827-43-4P 305827-66-1P 305827-76-3P 305827-78-5P 305827-80-9P 305827-97-8P 305827-99-0P 305828-03-9P 305828-13-1P 305828-19-7P 305828-21-1P 305828-30-2P 305828-37-9P 305828-38-0P 305828-41-5P 305828-42-6P 305829-95-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-26-8 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-28-0 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305822-29-1 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 305822-30-4 CAPLUS

CN Carbamic acid, [3-(1H-imidazol-1-yl)propyl]-, (4bS,7R,8aR)-. 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-31-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ R \end{array}$$

RN 305822-32-6 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} Ph \\ \hline \\ N \\ \hline \\ OH \\ H \end{array}$$

RN 305822-33-7 CAPLUS

CN Carbamic acid, [2-(3-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-34-8 CAPLUS

CN Carbamic acid, (2-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-35-9 CAPLUS

CN Carbamic acid, [2-(2-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-36-0 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ \hline \\ N \\ \hline \\ OH \\ \end{array}$$

RN 305822-37-1 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-38-2 CAPLUS

CN Carbamic acid, [2-(4-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305822-39-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-20-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-methoxy-4b-(2-methoxyethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-21-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-methoxyethyl)-2-phenanthrenyl 03/18/2003

ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-22-3 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b-[2-[2-(dimethylamino)-2-oxoethoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-44-9 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-45-0 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 305825-46-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-48-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$n-Bu$$
 NMe_2
 R
 R
 R
 R
 R

RN 305826-86-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.

RN 305826-91-9 CAPLUS

CN Carbamic acid, dimethyl-, 4-[[(4aS,10aS)-7-[[(dimethylamino)carbonyl]oxy]-1,3,4,9,10,10a-hexahydro-2-hydroxy-2-propyl-4a(2H)-phenanthrenyl]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305826-93-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aS)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[[4-[(1-methylethyl)amino]phenyl]methyl]-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305826-98-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aR)-4b-[[4-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-03-6 CAPLUS

CN 2,7-Phenanthrenediol, 4a-[[3-(dimethylamino)phenyl]methyl]1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, 7-carbamate, (4aS,10aR)(9CI) (CA_INDEX_NAME)

Absolute stereochemistry.

$$Me_2N$$
 NH_2
 NH_2
 NH_2

RN 305827-05-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-06-9 CAPLUS

CN Acetamide, N-[4-[[(4aS,10aR)-7-[(aminocarbonyl)oxy]-1,3,4,9,10,10a-hexahydro-2-hydroxy-2-(1-propynyl)-4a(2H)-phenanthrenyl]methyl]phenyl]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-08-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-11-6 CAPLUS

CN 2,7-Phenanthrenediol, 4a-[[3-(dimethylamino)phenyl]methyl]1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, 7-(methylcarbamate),
(2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-14-9 CAPLUS

CN Carbamic acid, 1H-1,2,4-triazol-3-yl-, (4bS,8aR)-4b-[[3-

(dimethylamino) phenyl] methyl] -4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl) -2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$Me_2N$$
 Me_2N
 Me_2

RN 305827-29-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Ph
$$C = C - Me$$
 Me_2N
 $(CH_2)_3$
 H
 O
 R

RN 305827-30-9 CAPLUS

CN Carbamic acid, dimethyl-, (2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl ester (9CI) (CA INDEX NAME)

RN 305827-43-4 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} Ph \\ R \end{array}$$

HCl

RN 305827-66-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b-[[4-(acetylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-76-3 CAPLUS

CN Carbamic acid, [2-(1-methyl-2-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{Ph} \\ \text{N} \\ \text{OH} \\ \text{H} \end{array}$$

RN 305827-78-5 CAPLUS

CN Carbamic acid, 3-pyridinyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-80-9 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-propenyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-97-8 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 305827-99-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305828-03-9 CAPLUS

CN Carbamic acid, (1H-tetrazol-5-ylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305828-13-1 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 305828-19-7 CAPLUS

CN Carbamic acid, (2-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} n-Pr \\ \\ N \\ \\ OH \\ \end{array}$$

RN 305828-21-1 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} n-Pr \\ \\ N \\ \\ OH \\ \end{array}$$

RN 305828-30-2 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)

(CA INDEX NAME)

Absolute stereochemistry.

RN 305828-37-9 CAPLUS

CN Carbamic acid, [2-(2-pyridinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305828-38-0 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Me (CH₂) 4

Me
$$R$$

OH

 R
 R
 R
 R
 R
 R

RN 305828-41-5 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305828-42-6 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305829-95-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-

octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 305823-17-0P 305823-64-7P 305823-65-8P 305823-66-9P 305823-67-0P 305823-68-1P 305823-69-2P 305823-70-5P 305823-71-6P 305823-72-7P 305823-74-9P 305823-76-1P 305823-78-3P 305823-82-9P 305823-84-1P 305823-86-3P 305823-88-5P 305830-68-6P 305830-69-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305823-17-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305823-64-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-(4-formylphenoxy)ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 305823-65-8 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-(4-morpholinylmethyl)phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305823-66-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4[(dimethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)

● HCl

RN 305823-67-0 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4[(ethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305823-68-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[(methylamino)methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 305823-69-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[[methyl(methylsulfonyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305823-70-5 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-4b-[2-[4-(1-pyrrolidinylmethyl)phenoxy]ethyl]-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 305823-71-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[(4-methyl-1-piperazinyl)methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

•x HCl

RN 305823-72-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[[methyl(1-methyl-4-piperidinyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

●x HCl

ÖН

H

RN 305823-74-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[[(2-methoxyethyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305823-76-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[[2-(dimethylamino)ethyl]amino]methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

●x HCl

RN 305823-78-3 CAPLUS

Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[[2-CN (dimethylamino) ethyl] methylamino] methyl] phenoxy] ethyl] -4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} \text{Me}_2\text{N} \\ \text{Me} \\ \text{C} \\ \text{C} \\ \text{OH} \\ \text{H} \\ \end{array}$$

x HCl

RN 305823-80-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[(diethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) INDEX NAME)

● HCl

RN 305823-82-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[(cyclopropylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305823-84-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[bis(2-methoxyethyl)amino]methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 305823-86-3 CAPLUS
CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-(4morpholinylmethyl)phenoxy]ethyl]-2-phenanthrenyl ester, monohydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 305823-88-5 CAPLUS
CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b-[2-[4[(dimethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7hydroxy-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 305830-68-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-oxoethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CHO
$$R$$
 $C = C - Me$

RN 305830-69-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-hydroxyethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$R$$
 C R C R R R

3

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

AB The enhancers are selected from compds. bearing triphenylene rings and used at 0.01-20 parts per 100 parts cellulose esters to attain a retardation value (Rth550) of 70-400 nm for a wave length of 550 nm across film thickness. Thus, cast molding a dope contg. cellulose acetate (acetylation degree 60.9%) 45, a 4-methoxybenzoyloxy group-contg. triphenylene (I) 0.59, methylene chloride 232.72, MeOH 42.57 and BuOH 8.50 parts gave a 100-.mu.m film with Rth550 179 nm, vs. 20 nm in the absence of the I.

ACCESSION NUMBER: 2000:705290 CAPLUS

DOCUMENT NUMBER: 133:297278

TITLE: Retardation enhancers for films of cellulose lower

fatty acid esters and their use in optical

compensation sheets of liquid-crystal display devices Matsuoka, Koujin; Kawata, Tadashi; Murayama, Masahiko

INVENTOR(S): Matsuoka, Koujin; Kawata, Tadash:
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 2000275434 A2 20001006 JP 1999-81891 19990325
PRIORITY APPLN. INFO.: JP 1999-81891 19990325

IT 300671-40-3

RL: POF (Polymer in formulation); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(for films of cellulose lower fatty acid esters and use in optical compensation sheets of liq.-crystal display devices)

RN 300671-40-3 CAPLUS

CN 2,3,6,7,10,11-Triphenylenehexol, hexakis(phenylcarbamate) (9CI) (CA INDEX NAME)

03/18/2003 Print selected from Online session

(FILE 'HOME' ENTERED AT 13:57:27 ON 18 MAR 2003)


	FILE	'REGIS	STRY	ENTERED	AT	13:57:42	ON	18	MAR	2003
L1			STRU	JCTURE UP	LOAI	DED				
L2		10	S L	L						
L3		10	S L	l						

136 S L1 FUL

L4

L5

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 18 MAR 2003 5 S L4



15 16 17 18 19 20 21
ring nodes:
 1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds:
 1-15 13-21 15-16 16-17 16-18 18-19 19-20
ring bonds:
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
exact/norm bonds:
 1-15 4-7 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14 13-21 15-16 16-17
 16-18 18-19 19-20
normalized bonds:
 1-2 1-6 2-3 3-4 4-5 5-6

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS

03/18/2003 10006215.trn

Connecting via Winsock to STN

NEWS 41

Jan 21

Welcome to STN International! Enter x:x LOGINID:ssspta1611hxl PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS "Ask CAS" for self-help around the clock NEWS Apr 08 BEILSTEIN: Reload and Implementation of a New Subject Area NEWS Apr 09 NEWS Apr 09 ZDB will be removed from STN NEWS Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS Apr 22 NEWS 8 Federal Research in Progress (FEDRIP) now available Apr 22 NEWS 9 Jun 03 New e-mail delivery for search results now available NEWS 10 Jun 10 MEDLINE Reload NEWS 11 Jun 10 PCTFULL has been reloaded NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment NEWS 13 Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid Enhanced polymer searching in REGISTRY NEWS 14 Jul 29 NEWS 15 Jul 30 NETFIRST to be removed from STN CANCERLIT reload NEWS 16 Aug 08 NEWS 17 Aug 08 PHARMAMarketLetter (PHARMAML) - new on STN NEWS 18 Aug 08 NTIS has been reloaded and enhanced Aquatic Toxicity Information Retrieval (AQUIRE) NEWS 19 Aug 19 now available on STN NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded The MEDLINE file segment of TOXCENTER has been reloaded NEWS 21 Aug 19 Sequence searching in REGISTRY enhanced NEWS 22 Aug 26 JAPIO has been reloaded and enhanced NEWS 23 Sep 03 Experimental properties added to the REGISTRY file NEWS 24 Sep 16 NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985 EVENTLINE has been reloaded NEWS 27 Oct 21 BEILSTEIN adds new search fields NEWS 28 Oct 24 NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002 NEWS 31 Nov 18 DKILIT has been renamed APOLLIT NEWS 32 Nov 25 More calculated properties added to REGISTRY TIBKAT will be removed from STN NEWS 33 Dec 02 NEWS 34 Dec 04 CSA files on STN NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date NEWS 36 Dec 17 TOXCENTER enhanced with additional content Adis Clinical Trials Insight now available on STN NEWS 37 Dec 17 NEWS 38 Dec 30 ISMEC no longer available NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003

NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

PHARMAML offering one free connect hour in February 2003

ENERGY, INSPEC

NEWS 43 Feb 13 CANCERLIT is no longer being updated

NEWS 44 Feb 24 METADEX enhancements

NEWS 45 Feb 24 PCTGEN now available on STN

NEWS 46 Feb 24 TEMA now available on STN

NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation

NEWS 48 Feb 26 PCTFULL now contains images

NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,

CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:54:19 ON 18 MAR 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:54:28 ON 18 MAR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8 DICTIONARY FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

Uploading 10006215.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:54:47 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 168 TO ITERATE

100.0% PROCESSED 168 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2583 TO 4137

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> d scan

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

03/18/2003

10006215.trn

=> s l1 ful

FULL SEARCH INITIATED 11:55:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3276 TO ITERATE

100.0% PROCESSED 3276 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01

r3

28 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.55 148.76

FILE 'CAPLUS' ENTERED AT 11:55:34 ON 18 MAR 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2003 VOL 138 ISS 12 FILE LAST UPDATED: 17 Mar 2003 (20030317/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4

4 L3

=> d abs ibib hitstr 1-YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

AB Title compd. (I) was prepd. via reaction of 4b(S)-Benzyl-7(S)-hydroxy-7-(3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2-carboxylic acid (II) with 3-aminomethyl-2-methylpyridine (III) in the presence of carbonyldiimidazole. Thus, II (prepn. given) and carbonyldiimidazole were refluxed 2 h in THF; III in THF was added followed by stirring for 3 h at room temp. to give 69% I.

ACCESSION NUMBER:

2002:330265 CAPLUS

DOCUMENT NUMBER:

136:340594

TITLE:

Preparation of 4b(S)-benzyl-7(S)-hydroxy-7-(3,3,3-

trifluoropropyl)-4b,5,6,7,8,8a(R),9,10-octahydrophenanthrene-2-carboxylic acid

(2-methylpyridin-3-ylmethyl)amide via an amidation

reaction using carbonyldiimidazole.

INVENTOR(S):

Murry, Jerry Anthony; White, Timothy Donald

PATENT ASSIGNEE(S):

Pfizer Products Inc., USA

SOURCE:

Eur. Pat. Appl., 53 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO	. KIND	DATE	APPLICATION NO.	DATE
-				
EP 120165	55 A2	20020502	EP 2001-309057	20011025
EP 120165	55 A3	20020626	•	
R: A	AT, BE, CH, DE	, DK, ES, FR	R, GB, GR, IT, LI, LU,	NL, SE, MC, PT,
I	E, SI, LT, LV	, FI, RO, MK	C, CY, AL, TR	
US 200208		20020704	US 2001-8619	20011022
CN 135631	.9 A	20020703	CN 2001-135596	20011026
JP 200219	3937 A2	20020710	JP 2001-329529	20011026
BR 200100)4836 A	20021015	BR 2001-4836	20011029
PRIORITY APPLN	I. INFO.:		US 2000-243873P P	20001027
OTHER SOURCE (S	CA:	SREACT 136:3	40594	

IT 418814-84-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of benzylhydroxytrifluoropropyloctahydrophenanthrenecarboxylic acid methylpyridinylmethylamide via an amidation reaction)

RN 418814-84-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

$$\mathbb{R}^2$$
 \mathbb{R}^1
 $\mathbb{R}^3\mathbb{R}^4\mathbb{N}$

Title compds. [I; R1 = (trifluoromethyl)alkyl, CF3, C.tplbond.CMe, AB C.tplbond.CCl, C.tplbond.CCF3, CH2OA; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H , alkylamino, alkylhet; R3R4N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring contg. 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R7; R7 = (substituted) alkyl; with provisos], were prepd. for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A soln. of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2ethyl-[2R-(2.alpha.,4a.alpha.,10a.beta.)] (prepn. given), COCl2, and Et3N in THF was stirred at room temp. for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS

DOCUMENT NUMBER:

136:340495

I

TITLE:

SOURCE:

Preparation of octahydrophenanthrenyl carbamates as

glucocorticoid receptor modulators

INVENTOR (S):

Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson,

Ralph Pelton, Jr.

PATENT ASSIGNEE(S):

Pfizer Products Inc., USA Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent English

LANGUAGE:

Engi

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT N	о.	KIND DA	ATE	APPLICATION	NO. DAT	re
EP 12016				EP 2001-3090		
R:	AT, BE, C	H, DE, D	OK, ES, FR,	GB, GR, IT, L	[, LU, NI	J, SE, MC, PT
	IE, SI, L	T, LV, F	FI, RO, MK,	CY, AL, TR		
JP 20021	93911	A2 20	020710	JP 2001-3280	050 200	011025
US 20021	07235	A1 20	020808	US 2001-621	200	011026
BR 20010	04831	A 20	020820	BR 2001-483	l ^{>} 200	011026
PRIORITY APPL	N. INFO.:		1	US 2000-243993I	P 200	001028
OTHER SOURCE (S):	MARPA	T 136:3404	95		
IT 418814-8	4-3P 4195	34-43-3F	419534-46	-6P		
419534-5	5-7P 4195	34-64-8F	419534-87	-5P		
419534-9	1-1P 4195	34-96-6F	419534-97	-7P		

419534-98-8P 419535-00-5P 419535-01-6P 419535-02-7P 419535-03-8P 419535-04-9P 419535-05-0P 419535-07-2P 419535-24-3P

419535-26-5P 419535-27-6P 419535-28-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators)

RN 418814-84-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

514/5.5

Absolute stereochemistry.

RINCOR carbanicacid

RINCOR carboxylic acid

PCOR'

RN 419534-43-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenylester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-46-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419534-55-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-64-8 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-87-5 CAPLUS

CN Carbamic acid, (2-amino-2-methylpropyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

RN 419534-91-1 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419534-96-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3$$
C OH H

RN 419534-97-7 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{N} \\ \text{CH}_2)_3 \end{array}$$

RN 419534-98-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-00-5 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-01-6 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-02-7 CAPLUS

CN Carbamic acid, [3-(ethylmethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

RN 419535-03-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-04-9 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-05-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-07-2 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-24-3 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

RN 419535-26-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 419535-27-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$Me_2N$$
Et

RN 419535-28-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} OH \\ R \end{array}$$

$$\begin{array}{c} OH \\ R \end{array}$$

$$\begin{array}{c} R \\ R \end{array}$$

$$\begin{array}{c} H \\ R \end{array}$$

$$\begin{array}{c} Me_2N \\ H \end{array}$$

2

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

03/18/2003 10006215.trn

ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS L4

Compns. and methods are provided for achieving a therapeutic effect, AB including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER:

2001:338070 CAPLUS

DOCUMENT NUMBER:

134:336224

TITLE:

Use of corticotropin releasing factor (CRF)

antagonists for treating syndrome X

INVENTOR(S):

Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): SOURCE:

Pfizer Products Inc., USA Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. --------------EP 1097709 **A2** 20010509 EP 2000-309441 20001026

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

ZA 2000006008 20020426 ZA 2000-6008 20001026 PRIORITY APPLN. INFO.: US 1999-162340P P 19991029

OTHER SOURCE(S):

MARPAT 134:336224

305822-31-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)

305822-31-5 CAPLUS RN

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (CA INDEX NAME)

Ι

II

$$\begin{array}{c} Ph \\ C \equiv C - Me \end{array}$$

Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = AΒ CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2,R3 = null when adjacent dashed line = bond; R4,R5 = H, cyano, alkyl, alkoxy,
etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7,R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14,R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un) substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepd. as glucocorticoid receptor modulators (no data). 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addn. with Me vinyl ketone in the presence of (S)-(-)-.alpha.-methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone deriv. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, redn. of the enone with lithium and ammonia, addn. of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid deriv. which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:790448 CAPLUS

DOCUMENT NUMBER: 133:350060

TITLE: Preparation of nonracemic octahydrophenanthrene and

other tricyclic derivs. as selective modulators of

glucocorticoid receptors

INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley

Paul; Swick, Andrew Gordon

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE				APPLICATION NO. DATE									
WO	2000066522			A1 20001109				WO 2000-IB366					20000327				
	W:	ΑE,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,
		CZ,	DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,
		IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,
		MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,
		SL,	ΤJ,	TM,	TR,	TT,	UΑ,	UG,	US,	UΖ,	VN,	ΥU,	ZA,	ZW,	AM,	ΑZ,	BY,
		KG,	KZ,	MD,	RU,	ТJ,	TM										
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,
		DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,
		CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG				
BR	2000010138			A 20020122				BR 2000-10138 20000327									
ΕP	1175383			A1 20020130				EP 2000-911172						20000327			
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO										
US	63802	223		B1 2002043			0430		US 2000-559384					2000	1427		
NO 2001005272							1228	NO 2001-5272					2001	1029			
US	20023	L473	36	A:	l	2002	1010		U	S 20	02-8	0174		2002	219		
PRIORITY APPLN. INFO.:							1	US 1	999-	1321	30P	P	1999	0430			
									WO 2	000-	IB36	6	W	2000	327		
								1	US 2	000-	5593	84	A 3	2000	0427		
	BR EP US NO US	RW: BR 20000 EP 11753 R: JP 20029 US 63802 NO 20010 US 20023	WO 200006652 W: AE, CZ, IS, MG, SL, KG, RW: GH, DK, CG, BR 200001013 EP 1175383 R: AT, IE, JP 200254316 US 6380223 NO 200100527 US 200214733	WO 2000066522 W: AE, AL, CZ, DE, IS, JP, MG, MK, SL, TJ, KG, KZ, RW: GH, GM, DK, ES, CG, CI, BR 2000010138 EP 1175383 R: AT, BE, IE, SI, JP 2002543169 US 6380223 NO 2001005272 US 2002147336	WO 2000066522 A: W: AE, AL, AM, CZ, DE, DK, IS, JP, KE, MG, MK, MN, SL, TJ, TM, KG, KZ, MD, RW: GH, GM, KE, DK, ES, FI, CG, CI, CM, BR 2000010138 A EP 1175383 A: R: AT, BE, CH, IE, SI, LT, JP 2002543169 T: US 6380223 B: NO 2001005272 A	WO 2000066522 A1 W: AE, AL, AM, AT, CZ, DE, DK, EE, IS, JP, KE, KG, MG, MK, MN, MW, SL, TJ, TM, TR, KG, KZ, MD, RU, RW: GH, GM, KE, LS, DK, ES, FI, FR, CG, CI, CM, GA, BR 2000010138 A EP 1175383 A1 R: AT, BE, CH, DE, IE, SI, LT, LV, JP 2002543169 T2 US 6380223 B1 NO 2001005272 A US 2002147336 A1	WO 2000066522 A1 20000 W: AE, AL, AM, AT, AU, CZ, DE, DK, EE, ES, IS, JP, KE, KG, KP, MG, MK, MN, MW, MX, SL, TJ, TM, TR, TT, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, DK, ES, FI, FR, GB, CG, CI, CM, GA, GN, BR 2000010138 A 20020 BR 2000010138 A 20020 R: AT, BE, CH, DE, DK, IE, SI, LT, LV, FI, JP 2002543169 T2 20020 US 6380223 B1 20020 US 6380223 B1 20020 US 2002147336 A1 20020	WO 2000066522 A1 20001109 W: AE, AL, AM, AT, AU, AZ, CZ, DE, DK, EE, ES, FI, IS, JP, KE, KG, KP, KR, MG, MK, MN, MW, MX, NO, SL, TJ, TM, TR, TT, UA, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, DK, ES, FI, FR, GB, GR, CG, CI, CM, GA, GN, GW, BR 2000010138 A 20020122 EP 1175383 A1 20020130 R: AT, BE, CH, DE, DK, ES, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 US 6380223 B1 20020430 NO 2001005272 A 20011228 US 2002147336 A1 20021010	WO 2000066522 A1 20001109 W: AE, AL, AM, AT, AU, AZ, BA, CZ, DE, DK, EE, ES, FI, GB, IS, JP, KE, KG, KP, KR, KZ, MG, MK, MN, MW, MX, NO, NZ, SL, TJ, TM, TR, TT, UA, UG, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, DK, ES, FI, FR, GB, GR, IE, CG, CI, CM, GA, GN, GW, ML, BR 2000010138 A 20020122 EP 1175383 A1 20020130 R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 US 6380223 B1 20020430 NO 2001005272 A 20011228 US 2002147336 A1 20021010 RITY APPLN. INFO.:	WO 2000066522 A1 20001109 W W: AE, AL, AM, AT, AU, AZ, BA, BB, CZ, DE, DK, EE, ES, FI, GB, GD, IS, JP, KE, KG, KP, KR, KZ, LC, MG, MK, MN, MW, MX, NO, NZ, PL, SL, TJ, TM, TR, TT, UA, UG, US, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, DK, ES, FI, FR, GB, GR, IE, IT, CG, CI, CM, GA, GN, GW, ML, MR, BR 2000010138 A 20020122 B EP 1175383 A1 20020130 E EP 1175383 A1 20020130 E ER AT, BE, CH, DE, DK, ES, FR, GB, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 J US 6380223 B1 20020430 U NO 2001005272 A 20011228 N US 2002147336 A1 20021010 U RITY APPLN. INFO.: US 1	WO 2000066522 A1 20001109 WO 20 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, CZ, DE, DK, EE, ES, FI, GB, GD, GE, IS, JP, KE, KG, KP, KR, KZ, LC, LK, MG, MK, MN, MW, MX, NO, NZ, PL, PT, SL, TJ, TM, TR, TT, UA, UG, US, UZ, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, DK, ES, FI, FR, GB, GR, IE, IT, LU, CG, CI, CM, GA, GN, GW, ML, MR, NE, EP 1175383 A1 20020122 BR 20 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 20 US 6380223 B1 20020430 US 20 NO 2001005272 A 20011228 NO 20 US 2002147336 A1 20021010 US 20 RITY APPLN. INFO.: US 1999- WO 2000-	WO 2000066522 A1 20001109 WO 2000-II W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, BR 2000010138 A 20020122 BR 2000-10 EP 1175383 A1 20020130 EP 2000-91 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-61 US 6380223 B1 20020430 US 2000-51 US 2002147336 A1 20021010 US 2002-80 RITY APPLN. INFO.: US 1999-13213	WO 2000066522 A1 20001109 WO 2000-IB366 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, BR 2000010138 A 20020122 BR 2000-10138 EP 1175383 A1 20020130 EP 2000-911173 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-615356 US 6380223 B1 20020430 US 2000-559386 NO 2001005272 A 20011228 NO 2001-5272 US 2002147336 A1 20021010 US 2002-80174 RITY APPLN. INFO.: US 1999-132130P WO 2000-IB366	WO 2000066522 A1 20001109 WO 2000-IB366 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2000010138 A 20020122 BR 2000-10138 EP 1175383 A1 20020130 EP 2000-911172 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-615356 US 6380223 B1 20020430 US 2000-559384 NO 2001005272 A 20011228 NO 2001-5272 US 2002147336 A1 20021010 US 2902-80174 RITY APPLN. INFO.: US 1999-132130P P WO 2000-IB366 W	WO 2000066522 Al 20001109 WO 2000-IB366 20006 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2000010138 A 20020122 BR 2000-10138 20006 EP 1175383 Al 20020130 EP 2000-911172 20006 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-615356 20006 US 6380223 Bl 20020430 US 2000-559384 20006 US 6380223 Bl 20020430 US 2000-559384 20006 US 2002147336 Al 20021010 US 2002-80174 20026 RITY APPLN. INFO:: US 1999-132130P P 19996	WO 2000066522 A1 20001109 WO 2000-IB366 20000327 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2000010138 A 20020122 BR 2000-10138 20000327 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-615356 20000327 US 6380223 B1 20020430 US 2000-559384 20000427 NO 2001005272 A 20011228 NO 2001-5272 20011029 US 2002147336 A1 20021010 US 2002-80174 20020219	WO 2000066522 A1 20001109 WO 2000-IB366 20000327 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2000010138 A 20020122 BR 2000-10138 20000327 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE, SI, LT, LV, FI, RO JP 2002543169 T2 20021217 JP 2000-615356 20000327 US 6380223 B1 20020430 US 2000-559384 20000427 NO 2001005272 A 20011228 NO 2001-5272 20011029 US 2002147336 A1 20021010 US 2002-80174 20020219 RITY APPLN. INFO.: US 1999-132130P P 19990430 WO 2000-IB366 W 20000327

OTHER SOURCE(S):

MARPAT 133:350060

IT 305822-31-5P 305825-48-3P 305827-05-8P 305827-29-6P 305827-43-4P 305827-99-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-31-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305825-48-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl

03/18/2003

ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$n-Bu$$
 NMe_2
 R
 R
 R
 R
 R
 R
 R

RN 305827-05-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-29-6 CAPLUS

CN .Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 305827-43-4 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 305827-99-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$n-Pr$$
 R
 R
 R
 R
 R
 R
 R

IT 305823-17-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305823-17-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

3

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

03/18/2003

=> d his

(FILE 'HOME' ENTERED AT 11:54:19 ON 18 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:54:28 ON 18 MAR 2003

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 28 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:55:34 ON 18 MAR 2003

L4 4 S L3

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 20.23 168.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE -2.60 -2.60

STN INTERNATIONAL LOGOFF AT 11:58:42 ON 18 MAR 2003